U.S. Healthcare Services Stock News

Leonardo DRS (DRS) has placed an order with Israel based Axon Vision for AI enabled counter unmanned aerial systems, extending a prior cooperation agreement and drawing fresh attention to the company’s role in advanced defense technology. See our latest analysis for Leonardo DRS. The Axon Vision order comes after a period of steady newsflow for Leonardo DRS, including fresh leadership appointments at the start of 2026 and an upcoming earnings call. The shares are at $40.85 following an 18.54%...

Wondering if Cheesecake Factory at around US$59.75 is offering you solid value or asking too much for its famous menu? This article walks through what that price could mean for you as a shareholder or a potential buyer. The stock shows returns of 5.7% over 7 days, 19.8% over 30 days, 13.1% year to date, 22.9% over 1 year, 70.9% over 3 years and 58.9% over 5 years, which gives useful context for judging the current share price. Recent coverage has focused on how Cheesecake Factory fits into...

In recent days, Ross Stores has drawn fresh attention after multiple major banks reiterated positive views on the off-price retailer, citing its ongoing store expansion, consistent comparable sales growth and solid post-earnings revenue and profit trends. Beyond near-term optimism, analysts are emphasizing Ross’s ability to pair its “treasure hunt” model with logistics upgrades and leadership transition to support further growth in underpenetrated markets. With analyst enthusiasm centered...

If you are wondering whether Shift4 Payments at around US$65.51 is a bargain or just fairly priced, you are not alone; many investors are asking the same question. The stock is up 4.5% year to date, although it shows a 35.9% decline over the last year, which can change how the market is viewing its potential and risk. Recent attention on Shift4 has centered on its position as a payments provider and how its business model fits into the broader US listed diversified financials sector. This...

Event driven look at AbbVie AbbVie (ABBV) has been drawing attention after recent share price moves, with the stock modestly positive over the past day but lower over the past week, month, and past 3 months. See our latest analysis for AbbVie. While the recent 7 day and 90 day share price returns are in decline, AbbVie’s 1 year and 5 year total shareholder returns of 30.14% and 136.37% indicate stronger longer term momentum. If AbbVie’s recent pullback has you thinking about opportunities in...

Host Hotels & Resorts (HST) is back in focus after multiple Wall Street firms, including Deutsche Bank and Baird, updated their views on the hotel REIT group as part of their 2026 sector outlooks. See our latest analysis for Host Hotels & Resorts. The recent analyst updates land after a mixed stretch for the stock, with a 14.33% 90 day share price return and 13.22% 1 year total shareholder return suggesting momentum has picked up compared with the shorter term. If this hotel REIT has caught...

On January 13, 2026, Recursion Pharmaceuticals presented at the 44th Annual J.P. Morgan Healthcare Conference, where CEO Najat Khan highlighted its AI-enabled drug discovery platform, clinical updates such as REC-4881 in familial adenomatous polyposis, and partnerships that have generated over US$500 million in upfront and milestone payments. The company also told investors it expects its current cash resources to last through the end of 2027, underscoring management’s focus on balancing...

Mosaic (MOS) has drawn fresh attention after agreeing to sell its Carlsbad, New Mexico potash operation for US$30 million, as analysts reassess the stock in light of margin pressures and industry headwinds. See our latest analysis for Mosaic. The Carlsbad sale comes after a mixed stretch for Mosaic, with a 1-day share price return of 1.91% and 7-day share price return of 4.17%, while the 1-year total shareholder return is slightly negative and the 3-year total shareholder return shows a much...

In recent days, several analysts have updated their views on Dominion Energy, revising earnings expectations ahead of its upcoming fourth-quarter results, with consensus now calling for profit of US$0.69 per share, about 19% higher than the same period a year ago. This refreshed analyst outlook, coming after Dominion Energy had previously exceeded Wall Street’s earnings estimates in each of the last four quarters, highlights growing attention on how its operations may be supporting improving...

If you are wondering whether Deckers Outdoor’s share price still reflects its true worth, you are not alone, and this article is built to help you frame that question clearly. The stock recently closed at US$101.71, with returns of a 5.4% decline over 7 days, 0.5% over 30 days, a 4.8% decline year to date, a 50.7% decline over 1 year, 45.3% over 3 years and 88.9% over 5 years, which can change how investors think about both risk and opportunity. The recent share price moves sit against a...

Papa John's International (PZZA) is rolling out a unified AI voice and text ordering system using Google Cloud technology. The initiative aims to streamline ordering, personalize deals, and handle complex orders across its global pizza chain. See our latest analysis for Papa John's International. That AI rollout comes after a mixed year for the stock, with a 90 day share price return of 29.54% decline and a 1 year total shareholder return of 4.01%. This suggests that shorter term momentum has...

Digi International recently launched SmartSense ONE, a unified, modular IoT platform built on its SmartSense and Jolt acquisition capabilities, and expanded Digi Ventus managed 5G connectivity solutions to channel partners, aiming to simplify compliance, monitoring, and connectivity across retail, food service, healthcare, and edge environments. By combining prescriptive analytics, automated monitoring, and fully managed cellular connectivity into scalable, multi-module offerings, Digi is...

Recent market attention around Old Dominion Freight Line (ODFL) has focused on its pricing resilience, service quality, and capital returns during a soft freight backdrop, alongside generally constructive analyst commentary and a positive read from investors on potential future demand. See our latest analysis for Old Dominion Freight Line. Those themes are showing up in the price action, with the share price at $171.65 after a 27.11% 90 day share price return. At the same time, the 1 year...

If you are wondering whether Dollar Tree is still reasonably priced after its strong run, this article will walk through what the current share price might be implying about future value. Dollar Tree shares last closed at US$137.37, with returns of 2.7% over 7 days, 5.8% over 30 days, 7.6% year to date and 95.8% over the past year. The 3 year and 5 year returns sit at a 7.0% decline and 27.1% respectively. Recent coverage around Dollar Tree has focused on how discount retailers are...

Genpact (G) recently published research on how a small group of companies are embedding agentic AI into core operations, highlighting four key enablers and real world scaling challenges that may be relevant for investors tracking the stock. See our latest analysis for Genpact. Genpact’s new AI research lands at a time when the stock’s recent 7 day and 30 day share price returns of 1.75% and 2.64% sit alongside a stronger 90 day share price return of 18.01%. The 1 year and 5 year total...

Why Schneider National (SNDR) is Back on Investors’ Radar Schneider National (SNDR) has drawn fresh attention after recent share price moves, with the stock showing different return patterns over the past month, past 3 months, and year. Investors are weighing those returns alongside its current earnings profile. See our latest analysis for Schneider National. With the share price now at US$28.80 and a 30 day share price return of 6.63% alongside a 90 day share price return of 26.98%, short...

In early January 2026, Argent Trust Company, as Trustee of Sabine Royalty Trust, declared a cash distribution of US$0.321550 per unit, payable on January 29, 2026 to unit holders of record on January 15, 2026, alongside an update on December 2025 revenues and timing of certain cash receipts. The disclosure that approximately US$619,084 of January 2024 revenue would be recorded in February, with an additional US$455,454 already received after January’s close, highlights how reporting timing...

Why General Dynamics Stock Is Back in Focus General Dynamics (GD) is back on investors’ radar after its technology unit secured a US$988 million U.S. Navy contract to modernize fleet systems, along with broader optimism around potential increases in future defense spending. See our latest analysis for General Dynamics. The recent U.S. Navy contract and earlier optimism around proposed U.S. defense budget growth have come alongside a 7.7% 1 month share price return and a 39.9% 1 year total...

SELLAS Life Sciences Group announced an agreement with IMPACT-AML under which the pan-European network will run a clinical study of SLS009, a selective CDK9 inhibitor, in combination with azacitidine and venetoclax for newly diagnosed high-risk acute myeloid leukemia patients across multiple European sites. By tapping into IMPACT-AML’s EU Mission Cancer-backed STREAM platform, SELLAS can broaden European patient access to SLS009 in a cost-efficient way while its separate REGAL Phase 3 AML...

For investors wondering whether First Busey is offering fair value at its current share price, or whether the recent trading range is creating an opportunity, this article walks through what the numbers are indicating about the stock. The shares last closed at US$23.70, with returns of a 2.4% decline over 7 days and a 5.8% decline over 30 days, while the 1-year and 5-year returns of 9.9% and 23.2% keep longer term holders focused on the broader context. Recent coverage has focused on how...

Moderna (MRNA) is back in focus after its J.P. Morgan Healthcare Conference update, where management lifted the 2025 revenue forecast to about US$1.9b, outlined lower operating expenses, and reaffirmed its 2026 growth and 2028 cash breakeven targets. See our latest analysis for Moderna. The revenue upgrade and cost guidance from the J.P. Morgan Healthcare Conference has come alongside a sharp shift in sentiment. Moderna’s 1 day share price return of 17.02% has fed into a 30 day return of...

Lennar (LEN) is on investor watch after recent trading left the stock with a year-to-date total return of 18.3%, compared with a 0.4% total return over the past year. See our latest analysis for Lennar. The recent 1-day share price return of 2.0% and 7-day share price return of 15.95% at a share price of $123.32 sit against a much more muted 1-year total shareholder return of 0.41% and a 5-year total shareholder return of 83.33%. This suggests short-term momentum has picked up after a more...

If you are wondering whether CME Group's current share price really lines up with its underlying worth, you are not alone. This article is designed to walk you through that question step by step. The stock closed at US$268.45, with a 7 day return of a 0.3% decline, a 30 day return of a 1.9% decline, a year to date return of a 0.5% decline, but a 1 year return of 18.1%, a 3 year return of 70.6% and a 5 year return of 68.8%. Recent attention on CME Group has been shaped by its role as a major...

If you are wondering whether ImmunityBio's recent share price makes sense or not, you are not alone; the stock has attracted attention from investors trying to work out what a fair value might look like. The share price closed at US$2.82, with returns of 31.8% over the last 7 days, 19.5% over the last 30 days and 39.6% year to date, while the 1 year return sits at 21.6% and the 3 year return at negative 40.5%. Recent news flow around ImmunityBio has focused on its clinical pipeline and...